The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
Үндсэн зохиолчид: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
Формат: | Өгүүллэг |
Хэл сонгох: | English |
Хэвлэсэн: |
BMC
2025-01-01
|
Цуврал: | BMC Complementary Medicine and Therapies |
Нөхцлүүд: | |
Онлайн хандалт: | https://doi.org/10.1186/s12906-025-04753-w |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
-н: Ana Pilar Pérez-Acevedo, зэрэг
Хэвлэсэн: (2020-12-01) -
Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
-н: Elmar Graessel, зэрэг
Хэвлэсэн: (2024-10-01) -
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
-н: Anna Gościniak, зэрэг
Хэвлэсэн: (2024-11-01) -
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
-н: Zackary Montoya, зэрэг
Хэвлэсэн: (2020-09-01) -
El cannabidiol y sus indicaciones en psiquiatría
-н: Juan Fernando Muñoz Ramírez
Хэвлэсэн: (2021-03-01)